Predictimmune – Parkwalk closes investment
We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Focal Point Positioning – University of Cambridge Enterprise Fund IV investment
Focal Point was founded in June 2015 with Dr Ramsey Faragher as CEO and CTO. The team had originally worked on a range of platforms seeking to improve the navigational and positioning systems on vehicles as diverse as submarines… Read More
Polypharmakos – University of Cambridge Enterprise Fund IV investment
Cambridge and Kew join forces to find new antimicrobial substances in plants The Parkwalk-mamanged University of Cambridge Enterprise Fund IV and Cambridge Enterprise have invested £500k in Polypharmakos Limited, a spin-out from the University of Cambridge and the… Read More
Cytora – Parkwalk closes follow-on Investment
We are pleased to announce that the University of Cambridge Enterprise Fund IV and the Parkwalk Opportunities Fund have closed an investment into Cytora, a geopolitical risk analytics spin-out from the University of Cambridge. Cytora is a pioneer in… Read More
Cambridge Touch Technologies – follow-on investment
We have recently made a follow-on investment in Cambridge Touch Technologies for the University of Cambridge Enterprise Fund IV, the Parkwalk UK Tech Fund VII and the Parkwalk Opportunities Fund in a series ‘A’ financing round. Cambridge Touch Technologies… Read More
PervasID – University of Cambridge Enterprise Fund IV investment
We are delighted to announce that the University of Cambridge Enterprise Fund IV, managed by Parkwalk, has invested in PervasID, a spin-out from the Department of Engineering. The company has developed a long-range passive Radio-Frequency Identification (RFID) tracking… Read More
Fluidic Analytics – University of Cambridge Enterprise Fund IV and Parkwalk investment
Parkwalk have recently closed an investment in Fluidic Analytics for the University of Cambridge Enterprise Fund IV and Parkwalk Funds. Fluidic Analytics is developing a line of tools for the rapid, accurate, cost-effective analysis of proteins and other biomolecular species. By… Read More
PsyOmics – University of Cambridge Enterprise Fund IV investment
We are delighted to announce that the University of Cambridge Enterprise Fund IV, managed by Parkwalk, has invested in PsyOmics, a spin-out from the Department of Chemical Engineering and Biotechnology. The company aims to utilise blood-based diagnostics to… Read More
DefiniGEN – Parkwalk closes follow on investment
Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund IV and Parkwalk Funds DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human… Read More
University of Cambridge Enterprise Fund IV launched
Parkwalk are delighted to announce the launch of the University of Cambridge Enterprise Fund IV. Launched in conjunction with Cambridge Enterprise, the University’s Technology Transfer and academic consulting subsidiary, the University of Cambridge Enterprise Funds offer alumni and investors the opportunity to invest in… Read More
Posted on February 22, 2016
Fund Managers Comments
Cambridge, UoCEF IV